Invesco Biotechnology & Genome ETF
PBE
71 hedge funds and large institutions have $61.8M invested in Invesco Biotechnology & Genome ETF in 2016 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 11 increasing their positions, 30 reducing their positions, and 21 closing their positions.
5.96% less ownership
Funds ownership: 29.43% → 23.47% (-6%)
17% less funds holding
Funds holding: 86 → 71 (-15)
49% less capital invested
Capital invested by funds: $121M → $61.8M (-$59.4M)
63% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 30
67% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 21
75% less funds holding in top 10
Funds holding in top 10: 4 → 1 (-3)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $11K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
+$1.06M |
| 2 |
CWM
Concert Wealth Management
San Jose,
California
|
+$1.05M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$881K |
| 4 |
SB
Suntrust Banks
Atlanta,
Georgia
|
+$614K |
| 5 |
VKH
Virtu KCG Holdings
New York
|
+$477K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$9.79M |
| 2 |
QA
Quantitative Advantage
Minnetonka,
Minnesota
|
-$6.25M |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$4.1M |
| 4 |
GKWIM
Gerber Kawasaki Wealth & Investment Management
Santa Monica,
California
|
-$2.71M |
| 5 |
BWP
Baldwin Wealth Partners
Marion,
Massachusetts
|
-$1.81M |
PBE Hedge Fund Activity: Q1 2016 in Review
71 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Invesco Biotechnology & Genome ETF (PBE) for Q1 2016, worth a combined $61.8M — down 49% from $121M a quarter earlier.
Sellers outnumbered buyers: 21 funds closed out of PBE and 7 opened new positions — a net loss of 14 holders — while 30 trimmed existing stakes and 11 added.
The largest buyer was Virtu Financial, adding an estimated $1.06M. The largest seller was Morgan Stanley, cutting an estimated $9.79M.
- 71 institutional investors held Invesco Biotechnology & Genome ETF (PBE) as of Q1 2016, down from 86 in Q4 2015.
- Funds reported $61.8M of Invesco Biotechnology & Genome ETF stock for Q1 2016, down 49% quarter-over-quarter.
- 7 funds opened new Invesco Biotechnology & Genome ETF positions in Q1 2016 and 21 closed out, a net change of -14 holders.
- The largest Invesco Biotechnology & Genome ETF buyer in Q1 2016 was Virtu Financial, an estimated $1.06M added.
- The largest Invesco Biotechnology & Genome ETF seller in Q1 2016 was Morgan Stanley, an estimated $9.79M sold.
Based on aggregated 13F filings for Q1 2016.